Noda, Yoshihiro

写真a

Affiliation

School of Medicine, Department of Neuropsychiatry (Shinanomachi)

Position

Project Associate Professor (Non-tenured)
Page Top ▲

Career 【 Display / hide 】

  • 2006
    -
    2008

    Graduate School of Medicine, University of Tokyo, Department of Functional Biology, COE special researcher

  • 2008
    -
    2011

    University of Tokyo Hospital, Department of Neuropsychiatry, Senior resident

  • 2009
    -
    2012

    The University of Tokyo, Department of Neuroscience, PhD candidate

  • 2017
    -
    2020

    Keio University, School of Medicine Department of Neuropsychiatry, Senior Lecturer (Assistant Professor)

  • 2017
    -
    Present

    Keio University, Multidisciplinary Translational Research Lab, Principal Investigator

display all >>

Page Top ▲
 

Research Areas 【 Display / hide 】

  • Life Science / Neuroscience-general

  • Life Science / Neuroscience-general

  • Life Science / Basic brain sciences (rTMS clinical study)

  • Life Science / Basic brain sciences (TMS-EEG neurophysiology)

  • Life Science / Psychiatry

display all >>

Page Top ▲

Research Keywords 【 Display / hide 】

  • Deep rTMS

  • EEG

  • MST

  • TMS

  • TMS-EEG

display all >>

Page Top ▲
 

Books 【 Display / hide 】

  • 月刊「細胞」2024年7月号 グリアは神経回路機能の主役か？

    野田賀大, （株）北隆館 ニューサイエンス社, 2024.07

    Scope: Topics from special edition ・人間の実存を規定する「神経可塑性」を標的とした経頭蓋磁気刺激ニューロモデュレーション

  • 月刊「細胞」2023年9月号 神経の再生 ―臨床に届く基礎研究

    野田賀大, （株）北隆館 ニューサイエンス社, 2023.08,  Page： 2

    Scope: Topics from special edition ・ヒトの記憶・学習を支える分子基盤から脳の行動表現型としての心までを架橋する「神経可塑性」をターゲットとした経頭蓋磁気刺激療法 －うつ病の神経可塑性仮説の観点から

    　View Summary

    Topics from special edition
    ・ヒトの記憶・学習を支える分子基盤から脳の行動表現型としての心までを架橋する「神経可塑性」をターゲットとした経頭蓋磁気刺激療法 －うつ病の神経可塑性仮説の観点から（野田 賀大）

  • 精神医学領域の論文を読みこなすキーワード100！

    野田 賀大, 株式会社 新興医学出版社, 2022.12

    Scope: 50. ニューロモデュレーション

  • うつ病に対するTMS療法Up-to-date 自分らしい生き方を求めて

    2022.06,  Page： 158

  • 精神科レジデントマニュアル

    三村 將, 医学書院, 2022.03,  Page： xiv, 364p

    Scope: TMS療法について

display all >>

Page Top ▲

Papers 【 Display / hide 】

  • Effects of short-term exposure to moderate amounts of alcohol on brain volume.

    Sakiko Tsugawa, Fumihiko Ueno, Mutsuki Sakuma, Hideaki Tani, Ryo Ochi, Ariel Graff-Guerrero, Yoshihiro Noda, Hiroyuki Uchida, Masaru Mimura, Shunji Oshima, Sachio Matsushita, Shinichiro Nakajima

    Neuropsychopharmacology reports 45 ( 1 ) e12500 2025.03

    Accepted

    　View Summary

    AIM: Although numerous studies have reported that chronic alcohol consumption causes brain volume reduction and cerebrospinal fluid volume increase, few studies have examined the acute effects of alcohol on brain structure. This study aims to investigate the short-term brain volume changes following alcohol administration. METHODS: Moderate doses of alcohol were administered intravenously to 18 healthy volunteers for a total of 90 min to achieve a blood alcohol concentration of 0.5 mg/mL. An alcohol clamp method combined with physiologically based pharmacokinetic modeling was used to achieve fine control over blood alcohol concentration. T1 images with 3T MRI were scanned at three time points: baseline, 0 min, and 90 min after the end of alcohol administration. Cortical, subcortical, and ventricular volumes were computed after segmentation with FreeSurfer. Repeated measures analysis of variance was used to evaluate longitudinal changes in brain volume at 96 regions. RESULTS: Acute alcohol administration increased bilateral lateral ventricular volumes, which lasted until 90 min after the end of alcohol injection. On the other hand, the volumes of total gray matter, left precentral cortex, left caudal middle frontal cortex, and left superior frontal cortex decreased after alcohol administration, but these changes disappeared 90 min after the end of alcohol administration. CONCLUSION: Acute injection of moderate doses of alcohol may enlarge ventricle volumes and reduce gray matter volumes. The transient volume changes caused by acute administration of alcohol may be related to changes in CSF flow and water content of brain tissue, which warrants further study.

  • Clinical comparison and genetic analysis in pheochromocytoma with primary aldosteronism.

    Mai X, Kometani M, Kato T, Aiga K, Karashima S, Aono D, Konishi S, Nishimoto K, Hosomichi K, Watanabe A, Noda Y, Takeda Y, Yoneda T

    Endocrine journal 72 ( 2 ) 193 - 203 2025.02

    ISSN  0918-8959

  • Left prefrontal intermittent theta-burst stimulation therapy for major depressive disorder: A real-world, multisite observational study in Japan.

    Yoshihiro Noda, Ryota Osawa, Yuya Takeda, Kyoshiro Fujii, Yuka Saijo, Taku Kajiya, Kana Takeishi, Sotaro Moriyama, Takashi Saeki, Shinichiro Nakajima, Ryosuke Kitahata

    Journal of affective disorders  2025.01

    Lead author, Corresponding author, Accepted,  ISSN  0165-0327

    　View Summary

    BACKGROUND: Although approved for treatment in 2018, the effectiveness of intermittent theta-burst stimulation (iTBS) in a real-world setting remains inadequately studied. This observational study investigated the real-world use of iTBS, a usual medical practice for depression, factors influencing its effectiveness, and differences in effectiveness between 600 and 1200 pulses. METHODS: Data from patients who received iTBS therapy for depression at four private clinics between January 2021 and April 2024 were extracted. Patients were assessed using the 17-item Hamilton Depression Rating Scale at baseline and after treatment completion. Correlation and multiple regression analyses were performed to investigate clinico-demographic factors and stimulation parameters associated with iTBS effectiveness. Safety was assessed using all relevant data, and effectiveness was evaluated using eligible samples. RESULTS: Among 538 patients meeting eligibility criteria for effectiveness evaluation (mean age 40.8 ± 13.8 years, 44.1 % women), 63 completed iTBS with 600 pulses, and 475 completed iTBS with 1200 pulses. Overall response and remission rates were 69.1 % and 53.7 %, respectively, with no significant difference in effectiveness between iTBS-600 and iTBS-1200. Multiple regression analysis indicated fewer depressive episodes (β = -0.103, t = -2.080, p = 0.038) and more treatment sessions (β = 0.134, t = 3.155, p = 0.002) may have contributed to the positive effect of iTBS therapy. The most common adverse event was stimulation site pain. No severe adverse events, such as seizure induction or manic switch, were observed. CONCLUSION: The results suggest the highly favorable effectiveness of iTBS therapy for major depressive disorder in real-world settings.

  • Cognitive Outcomes After Transcranial Magnetic Stimulation for the Treatment of Late-Life Depression: Résultats cognitifs après la stimulation magnétique transcrânienne pour le traitement de la dépression chez les personnes âgées.

    Katharina Göke, Shawn M McClintock, Linda Mah, Tarek K Rajji, Hyewon H Lee, Sean M Nestor, Jonathan Downar, Yoshihiro Noda, Zafiris J Daskalakis, Benoit H Mulsant, Daniel M Blumberger

    Canadian journal of psychiatry. Revue canadienne de psychiatrie    7067437251315515 - 7067437251315515 2025.01

    Accepted,  ISSN  0706-7437

    　View Summary

    BACKGROUND: Late-life depression (LLD) is often accompanied by cognitive impairment, which may persist despite antidepressant treatment. Repetitive transcranial magnetic stimulation (rTMS) is an efficacious treatment for depression, with potential benefits on cognitive functioning. However, research on cognitive effects is inconclusive, relatively sparse in LLD, and predominantly focused on group-level cognitive changes. This study aimed to explore individual-level cognitive changes following rTMS treatment in patients with LLD. METHOD: Data were analyzed from 153 patients with LLD from the FOUR-D study (ClinicalTrials.gov identifier: NCT02998580) who received bilateral standard rTMS or theta burst stimulation (TBS) targeting the dorsolateral prefrontal cortex (DLPFC). Cognitive function was assessed pre- and post-treatment using measures of executive function, information processing speed, and learning and memory. Reliable change indices, adjusted for practice effects and test-retest reliability, were employed to evaluate individual-level cognitive changes. Chi-square tests examined if proportions of cognitive improvers differed from expected proportions. RESULTS: Cognitive performance from baseline to end of treatment remained stable for most patients. Reliably improved performance was observed in 0.0% to 20.0% of participants across cognitive measures, while worsened performance was observed in 0.0% to 2.7%. A small but significant proportion (20.0%) of participants showed improvement in verbal learning. CONCLUSIONS: Bilateral standard rTMS or TBS of the DLPFC in LLD yielded no substantial cognitive enhancing effects, although a small proportion showed improved verbal learning after treatment. Importantly, both interventions were cognitively safe with relatively stable performance across time. Future research is needed to explore approaches to enhance the cognitive benefits of standard rTMS and TBS in patients with LLD.

  • Effectiveness of sequential bilateral repetitive transcranial stimulation versus bilateral theta burst stimulation for patients with treatment-resistant depression (BEAT-D): a randomized non-inferiority clinical trial.

    Masataka Wada, Shinichiro Nakajima, Keita Taniguchi, Shiori Honda, Yu Mimura, Ryo Takemura, Kevin E Thorpe, Sakiko Tsugawa, Ryosuke Tarumi, Sotaro Moriyama, Naohiro Arai, Ryosuke Kitahata, Hiroyuki Uchida, Shinsuke Koike, Zafiris J Daskalakis, Masaru Mimura, Daniel M Blumberger, Yoshihiro Noda

    Brain stimulation 18 ( 1 ) 25 - 33 2025.01

    Last author, Corresponding author, Accepted,  ISSN  1935861X

    　View Summary

    BACKGROUND: Bilateral repetitive transcranial magnetic stimulation (BL-rTMS) over the dorsolateral prefrontal cortex is effective for treatment-resistant depression (TRD). Owing to a shorter treatment time, bilateral theta burst stimulation (BL-TBS) can be more efficient protocol. The non-inferiority of BL-TBS to BL-rTMS was established in late-life TRD; however, this has not been determined in adults of other age groups. Therefore, we investigated the non-inferiority in efficacy of BL-TBS versus BL-rTMS for TRD across a wide range of ages in a randomized, single-blind, multicenter trial. METHODS: The study included 180 participants with major depressive disorder (moderate or greater severity) who were unresponsive to at least one antidepressant treatment between September 2018 and July 2022. Following venlafaxine treatment, patients were randomly assigned to BL-rTMS or BL-TBS (1:1 ratio). The primary outcome was baseline-adjusted Montgomery-Åsberg Depression Rating Scale scores at 6 weeks. The non-inferiority margin of -3.86 was compared against the baseline-adjusted difference. Secondary outcomes included other depression rating scales. RESULTS: Seventy-seven patients were randomly assigned to BL-rTMS and 81 to BL-TBS, of whom 73 and 76 were assessed for the primary outcome, respectively. There was a -2.44 point difference, favoring BL-rTMS (one-tailed lower 95% CI=-4.19, p=0.091 for non-inferiority), and non-inferiority of BL-TBS was not established. However, non-inferiority was observed for secondary outcomes. The all-cause dropout rates and number of adverse effects were similar between them. CONCLUSION: Our study could not establish the non-inferiority of BL-TBS compared to BL-rTMS in terms of efficacy for patients with TRD across the adult lifespan.

display all >>

Page Top ▲

Reviews, Commentaries, etc. 【 Display / hide 】

  • 人間の実存を規定する「神経可塑性」を標的とした経頭蓋磁気刺激ニューロモデュレーション

    野田 賀大

    細胞 ((株)ニュー・サイエンス社)  56 ( 8 ) 607 - 608 2024.07

    ISSN  1346-7557

    　View Summary

    記憶と学習は,ヒトの脳機能発現の基礎を司っており,それらの積み重ねによって,個人の性格や人格,ひいてはその人の人生が形作られる。その分子基盤の鍵を握るのがNMDA受容体をはじめとしたグルタミン酸システムであり,そのカウンターパートを抑制性のGABA作動性システムが担っている。そして,記憶と学習を成立させている神経基盤の性質そのものを「神経可塑性」と呼ぶ。神経可塑性には,生理学的(機能的)な現象とシナプス可塑性をはじめとした解剖学的(構造的)な変化の両方が含まれる。精神神経疾患の多くは,その「神経可塑性」の障害によって引き起こされることが知られている。本稿では,うつ病の病態仮説の一つである「神経可塑性仮説」とその神経可塑性をニューロモデュレートすることで,当該機能を正常化させ,治療効果を発揮する治療法である磁気刺激療法について解説する。(著者抄録)

  • 治療抵抗性うつ病に対する反復経頭蓋磁気刺激療法への反応性に関連した神経生理学的マーカーの探索

    和田 真孝, 中島 振一郎, 谷口 敬太, 本多 栞, 高野 万由子, 三村 悠, 盛山 宗太郎, 三村 將, 野田 賀大

    日本生物学的精神医学会誌 (日本生物学的精神医学会)  35 ( 2 ) 94 - 94 2024.06

    ISSN  2186-6619

  • Exploring Optimal Neuroplasticity: Neuromodulation for Enhanced Human Well-Being.

    Yoshihiro Noda

    Journal of integrative neuroscience 23 ( 8 ) 155 - 155 2024

    Lead author, Last author, Corresponding author,  ISSN  02196352

  • Questionnaire Survey on Current Situation and Request of rTMS Therapy for Patients with Treatment-resistant Depression under Public Health Insurance in Japan

    高橋隼, 高橋隼, 高橋隼, 高橋隼, 松田勇紀, 松田勇紀, 鬼頭伸輔, 鬼頭伸輔, 中村元昭, 伊津野拓司, 野田賀大, 野田賀大

    精神神経学雑誌 126 ( 9 )  2024

    Last author, Corresponding author,  ISSN  0033-2658

  • 電場シミュレーションと機能的結合性解析を組み合わせた治療抵抗性うつ病に対する経頭蓋磁気刺激治療効果予測

    副島 祐太郎, 飯野 杏菜, 和田 真孝, 本田 栞, 高野 万由子, 中島 振一郎, 関野 正樹, 野田 賀大

    日本生体磁気学会誌 (日本生体磁気学会)  37 ( 1 ) 108 - 109 2024

    ISSN  0915-0374

display all >>

Page Top ▲

Research Projects of Competitive Funds, etc. 【 Display / hide 】

  • 神経伝達障害に基づく層別化を基盤とした、治療抵抗性うつ病への新規治療の開発

    2024.04
    -
    2027.03

    日本学術振興会, 科学研究費助成事業, 基盤研究(C), Coinvestigator(s)

  • 治療抵抗性統合失調症に対する最新鋭ニューロモジュレーションの開発

    2022.04
    -
    2026.03

    日本学術振興会, 科学研究費助成事業 基盤研究(B), 基盤研究(B), No Setting

  • Elucidating the gut-brain interaction in depression using functional brain imaging

    2022.04
    -
    2025.03

    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C), Grant-in-Aid for Scientific Research (C), No Setting

  • Development of Novel Neuromodulation Targeting the Neural Basis of Autism Spectrum Disorders

    2021.04
    -
    2025.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Yoshihiro Noda, Shinichiro Nakajima, Grant-in-Aid for Scientific Research (B), Principal investigator

  • The Brain of Musicians: A Cross Sectional Functional Neuroimaging Study with MRS, TMS and EEG

    2020.04
    -
    2023.03

    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B), Grant-in-Aid for Scientific Research (B), No Setting

    　View Summary

    音楽家の脳機能の解明を目的とし、音楽リズム処理機能と精神疾患の関連性、音楽リズム処理や和音処理機能の神経基盤、音楽演奏評価と視覚情報の関連性、音楽家の身体運動制御やドラマージストニアの身体症状の解明等、以下(1)-(7)の研究を推進した。(1) 前年度に引き続き、研究分担者と連携してマルチモーダル脳機能イメージング手法(核磁気共鳴画像法 [MRI]、核磁気共鳴スペクトロスコピー法 [MRS]、経頭蓋磁気刺激[TMS]-高解像度脳波[EEG]の同時計測法 [TMS-EEG])を用いた実験調査を継続して推進した。(2) 精神疾患、特に統合失調症患者の音楽リズム機能をハーバードビート評価テスト（H-BAT）を用いて評価し、治療抵抗性、精神症状、認知機能との関連性を調査し、患者の認知機能の低下が音楽リズム機能の低下と関連していること、及び、治療抵抗性によって音楽リズム生成機能に差異があることを明らかにした。(3) 音楽リズム機能とMRSで評価した脳内グルタミン酸濃度との関連性についてデータ分析を進めた。(4) 協和音の嗜好性と安静時脳機能ネットワークの関連性について、左側坐核ー右上頭頂回、前帯状回ー後上側頭回の安静時脳機能ネットワークが協和音の嗜好性に関連している可能性を得た。(5)演奏評価判断中の視聴覚情報処理過程について調査し、演奏評価判断時の視聴覚情報処理過程が音楽経験によって異なる可能性を得た。(6)ドラマー・パーカッショニストのリズム生成機能や音楽家のジストニア症状とリズム同期誤差・筋活動の関連性について調査・分析した。(7)その他、音楽リズムと身体運動の共鳴をテーマとし、音楽リズムと身体運動に関する研究が人類の起源・脳・身体機能の解明にもたらす意義について、総説・解説記事をまとめて発表した。

display all >>

Page Top ▲

Intellectual Property Rights, etc. 【 Display / hide 】

  • ノイズ判定装置、ハイブリッドモデル、ノイズ判定方法、プログラム、及び、端末装置

    Date applied： 特願2023-098479  2023.06 

    Date announced： 特開2024-179548  2024.12 

    Patent

  • 精神疾患判定装置、学習済みモデル、精神疾患判定補助方法、プログラム、及び、端末装置

    Date applied： 特願2023-098482  2023.06 

    Date announced： 特開2024-179550  2024.12 

    Patent

Page Top ▲

Awards 【 Display / hide 】

  • PCN Reports Reviewer Awards 2023

    野田 賀大, 2024, The Japanese Society of Psychiatry and Neurology

    Type of Award： Honored in official journal of a scientific society, scientific journal

  • Asian Journal of Psychiatry Outstanding Reviewer Recognition

    Yoshihiro Noda, 2024, Asian Journal of Psychiatry (Elsevier)

  • Neuropsychopharmacology Reports (NPPR) Reviewer Award 2022

    Yoshihiro Noda, 2022, The Japanese Society of Neuropsychopharmacology

  • International Conference Presentation Award

    Yoshihiro Noda, 2020, Japanese Society of Biological Psychiatry, Evaluation and Induction of neuroplasticity in patients with depression

  • International Conference Presentation Award, Symposium Organization Presentation Division

    Yoshihiro Noda, 2020, The Japanese Society of Psychiatry and Neurology, rTMS research in depression

display all >>

Page Top ▲
 

Courses Taught 【 Display / hide 】

  • ADVANCED STUDIES IN HUMAN SCIENCES 23A

    2024

  • ADVANCED STUDIES IN HUMAN SCIENCES 23A

    2023

  • ADVANCED STUDIES IN HUMAN SCIENCES 23A

    2022

  • ADVANCED STUDIES IN HUMAN SCIENCES 23A

    2021

  • ADVANCED STUDIES IN HUMAN SCIENCES 23A

    2020

display all >>

Page Top ▲

Courses Previously Taught 【 Display / hide 】

  • 保健医療分野の関する理論と支援の展開（臨床心理学専攻）

    国際医療福祉大学赤坂キャンパス

    2024
    -
    Present
    , 

    Postgraduate

  • Faculty of Medicine Systematic Lecture: Biological Psychiatry

    Keio University School of Medicine

    2022.05

  • 精神科臨床ー精神医学研究をつなぐセミナーシリーズ

    東京大学心の多様性と適応の連携研究機構／大学院総合文化研究科進化認知科学研究センター小池研究室

    2022.01

  • The Brain of Musicians: An Introduction to Neurosciences and Music with TMS and EEG

    Keio University, Faculty of Environment and Information Studies

    2020.08
    , 

    Other

  • 人間科学特殊ⅩⅩⅢＡ（精神医学）

    慶應義塾大学文学部人間科学専攻

    2018
    -
    Present

display all >>

Page Top ▲
 

Media Coverage 【 Display / hide 】

  • Can TMS Lift the “Brain Fog” of Long COVID?

    Psychiatric Times, Psychiatric Times (Transcranial magnetic stimulation treatment appeared to lessen some neuropsychiatric symptoms of long COVID in an open-label pilot study.) , 2023.08

  • 頭部へ磁気治療、データベース構築へ

    共同通信社, 毎日新聞 (くらしナビ・医療) , 2024.09

  • 「コロナで頭がアホになった」のツイートが話題。コロナ後遺症“ブレインフォグ”の恐ろしすぎる実態「集中力が続かない」「家事の途中で何をしていたか忘れる」対策と最近注目の治療法とは…

    集英社オンライン, 2024.08

  • 坪田ラボ---「うつ病」を対象としたTLG-005の特定臨床研究結果の速報

    共同通信社, 2024.07

    　View Summary

    坪田ラボ<4890>は9日、同社が実施した「うつ病」に対するTLG-005(バイオレットライトメガネ)の安全性と有効性を評価した特定臨床研究結果の速報を発表した。

    本研究は、慶應義塾大学医学部精神・神経内科学教室野田賀大先生等の協力のもと、2021年8月に開始、大うつ病性障害と診断された患者70例が登録され、全例で被験機器(バイオレット光照射)及び対照機器を照射した。

    主要評価項目については、機器の使用開始前から照射後までのMADRSスコアの変化量に関して，研究計画書に適合した患者だけを対象にしたデータ解析で、被験機器は対照機器に対して有意な改善効果が確認された。 疾病等の発生状況については、重症度が高度な有害事象，重篤な有害事象は発生しなかった。

    本研究において重篤な有害事象は認められず、「大うつ病性障害」に対する有効性を示す結果が得られた。この結果を受けて、同社は引き続き研究及び事業開発に取り組んでいく。

  • Study Published on Treating Long-COVID Symptoms

    The Penmark, 2024.01

    　View Summary

    The global COVID-19 pandemic has created immense pressure on patients, medical systems, and communities. While most who recover from the illness are able to return to their regular lives, still others experience persisting neurological and physical symptoms, a condition known as “Long-COVID.” In a recent study, Project Associate Professor Yoshihiro Noda from Keio University’s Department of Neuropsychiatry worked together with other clinics and psychiatrists to see the effects of transcranial magnetic stimulation (TMS) treatment on Long-COVID patients in a retrospective observational study using registry data at TMS clinics. Their analysis showed that this approach may be beneficial in treating cognitive dysfunction and depressive symptoms associated with Long-COVID.

    TMS is a treatment that uses magnetic fields to stimulate electrical currents in the brain. While this form of TMS treatment is still new, the results warrant further investigation into how neuropsychiatric care can help patients who are still experiencing the long-term effects of COVID-19.

    Based on the findings from this study, Dr. Noda and his colleagues are now pursuing a sham-controlled randomized trial of Long-COVID in Tokyo, Japan.

display all >>

Page Top ▲

Committee Experiences 【 Display / hide 】

  • 2024.03
    -
    Present

    実行委員, 日本ヒト脳マッピング学会

  • 2024.02
    -
    Present

    Guest Professor, Laboratory of the Neuropsychology and Cognitive Neurosciences Research Center of Universidad Católica del Maule, Chile

  • 2023.09
    -
    Present

    神経精神疾患のバイオマーカー検討委員会 委員, 日本臨床神経生理学会

  • 2023
    -
    Present

    プログラム委員, NEURO2024大会組織

  • 2022
    -
    Present

    Associate Editor, Editorial Board of Neuroimaging and Stimulation, Frontiers in Psychiatry

display all >>

Page Top ▲